Quotient’s comprehensive drug product expertise spans all types of oral dosage forms, a broad range of solubilisation technologies and high potency handling capabilities
Quotient Sciences, a leading drug development services organisation, and Druggability Technologies (DRGT), a specialty pharmaceutical company, have announced a collaboration to utilise Quotient’s integrated Translational Pharmaceutics platform to advance the development of DRGT-46, a novel, fast-acting formulation of celecoxib using proprietary super-API compositions developed by DRGT.
This will be Quotient’s first Translational Pharmaceutics program delivered from its US operating facilities.
Within the programme of work, DRGT is accessing Quotient’s unique Translational Pharmaceutics platform.
This involves the development of amorphous spray-dried formulations and GMP clinical trial manufacturing in Philadelphia followed by clinical dosing and taste assessment at Quotient’s clinical pharmacology unit in Miami.
The programme is fully adaptive, which will enable DRGT to optimise the drug product in response to emerging clinical data. Quotient will then seamlessly scale up the selected product to support pivotal patient trials.
Translational Pharmaceutics transforms the traditional model of outsourcing to disparate contract CDMOs and CROs by integrating formulation development, real-time adaptive GMP manufacturing and clinical research.
It is proven to accelerate development timelines and reduce overall costs and has been applied in more 350 programmes for customers worldwide.
In 2017, Quotient established the capability to run Translational Pharmaceutics programmes in the US Following a Critical Path Innovation Meeting with the FDA’s Office of Translational Sciences, and meetings with local institutional review boards, Quotient is now delivering programmes in the US.
“We have significantly expanded our CDMO and CRO operations in the US and are now performing integrated programmes in the world’s largest R&D market,” said Mark Egerton, PhD, CEO of Quotient. “This offers significant advantages to our customers. We are delighted to support DRGT on accelerating DRGT-46 as a new treatment for acute and chronic pain.”
Gábor Heltovics, CEO of DRGT, added: “We are very pleased to be working with Quotient on this accelerated development project with our proprietary super-API technology."
"Quotient’s tight integration of formulation, manufacturing and clinical research services has enabled DRGT to execute an efficient development plan with a single outsourcing partner and, most importantly, reduce our time to market.”